<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271244</url>
  </required_header>
  <id_info>
    <org_study_id>RAM 6-7-2008</org_study_id>
    <nct_id>NCT01271244</nct_id>
  </id_info>
  <brief_title>Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder</brief_title>
  <official_title>Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder Among Veterans of Operation Enduring Freedom and Iraqi Freedom (OEF/OIF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Nebraska Western Iowa Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Nebraska Western Iowa Health Care System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study looked at relationship between escitalopram and heart rate variability and QT
      variability in veterans with PTSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are studying if taking escitalopram will normalize heart rate variability
      and a decrease (or no effect implying a lack of serious cardiac side effects) including QT
      variability in veterans with PTSD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.To Investigate the Effects of Escitalopram on Cardiac Vagal Function as Measured by R-R Interval Variability, Especially in the HF (0.15-0.5 Hz) Band in OEF/OIF Veterans With PTSD.</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To Investigate the Effects of Escitalopram on an Absolute or Relative Decrease in Cardiac Sympathetic Function and Serious Cardiac Side Effects as Measured by QT Interval Variability in OEF/OIF Veterans With PTSD.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>PTSD Depression Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escitalopram 10-20 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Depression Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escitalopram 10-20 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10-20mg daily for 12 weeks</description>
    <arm_group_label>PTSD Depression Group</arm_group_label>
    <arm_group_label>Major Depression Group</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria - Group I

          -  Patients, men and women between 19 and 55 years of age, inclusive.

          -  Patients with diagnosis of Posttraumatic Stress Disorder as determined by
             Mini-International Neuropsychiatric Interview (M.I.N.I.).

          -  Patients, who are able to comprehend and satisfactorily comply with protocol
             requirements and have an ability to read and write English.

          -  Patients, who signed the written informed consent given prior to entering any study
             procedure.

          -  Inclusion Criteria - Group II

          -  Patients, men and women between 19 and 55 years of age, inclusive.

        -Patients with diagnosis of Major Depression as determined by Mini- International
        Neuropsychiatric Interview (M.I.N.I.). A diagnosis of PTSD will be exclusionary.

          -  Patients, who are able to comprehend and satisfactorily comply with protocol
             requirements and have an ability to read and write English.

          -  Patients, who signed the written informed consent given prior to entering any study
             procedure.

        Exclusion Criteria:

          -  History of cardiovascular disease or a history of hypertension.

          -  Patients with a concurrent DSM-IV diagnosis in any of the following categories as
             determined by the M.I.N.I.

          -  Lifetime Schizophrenia and Schizoaffective Disorder

          -  Lifetime Bipolar I Disorder

          -  Substance Dependence or Abuse (excluding nicotine) within one month prior to the
             Screening Visit.

          -  Patients with a history of intolerance or hypersensitivity to escitalopram or
             citalopram.

          -  Patients who based on history or mental status examination have a significant risk of
             committing suicide. Current suicide risk (past month) will be assessed using the MINI
             Suicidality Module. Subjects considered at high suicide risk based on the module (&gt; 17
             points) will be excluded from study participation.

          -  Patients who are homicidal or violent and who are in the Investigator's opinion in
             significant imminent risk of hurting others.

          -  Subjects will be excluded who have a history of significant medical illness and who
             are on medications that affect cardiac and/or autonomic function.

          -  Female patients who are pregnant, planning to become pregnant, or if of childbearing
             potential, not using an acceptable method of birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Ramaswamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Veterans Affairs/NWIHCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Omaha Veterans Affairs Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <results_first_submitted>October 2, 2014</results_first_submitted>
  <results_first_submitted_qc>October 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 7, 2014</results_first_posted>
  <last_update_submitted>October 2, 2014</last_update_submitted>
  <last_update_submitted_qc>October 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Nebraska Western Iowa Health Care System</investigator_affiliation>
    <investigator_full_name>SRIRAM RAMASWAMY</investigator_full_name>
    <investigator_title>Staff Psychiatrist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PTSD Depression Group</title>
          <description>Veterans with PTSD and depression will receive Escitalopram: 10-20mg daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Major Depression Group</title>
          <description>Veteran with Depression only will receive Escitalopram: 10-20mg daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PTSD Depression Group</title>
          <description>Veterans with PTSD and Depression will receive Escitalopram: 10-20mg daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Major Depression Group</title>
          <description>Veterans with Depression only will receive Escitalopram: 10-20mg daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>YEARS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="2.4"/>
                    <measurement group_id="B2" value="30" spread="4.1"/>
                    <measurement group_id="B3" value="29" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1.To Investigate the Effects of Escitalopram on Cardiac Vagal Function as Measured by R-R Interval Variability, Especially in the HF (0.15-0.5 Hz) Band in OEF/OIF Veterans With PTSD.</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTSD Depression Group</title>
            <description>Veterans with PTSD and depession will receive Escitalopram: 10-20mg daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Major Depression Group</title>
            <description>Veterans with major depression onny receive Escitalopram: 10-20mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>1.To Investigate the Effects of Escitalopram on Cardiac Vagal Function as Measured by R-R Interval Variability, Especially in the HF (0.15-0.5 Hz) Band in OEF/OIF Veterans With PTSD.</title>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="941" spread="16"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Investigate the Effects of Escitalopram on an Absolute or Relative Decrease in Cardiac Sympathetic Function and Serious Cardiac Side Effects as Measured by QT Interval Variability in OEF/OIF Veterans With PTSD.</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PTSD Depression Group</title>
          <description>Veterans with PTSD and depression will receive Escitalopram: 10-20mg daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Major Depression Group</title>
          <description>Veterans with Major Depression only receive Escitalopram: 10-20mg daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to small number of subjects recruited in major depression groupwe are unable to compare to the PTSD group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>SRIRAM RAMASWAMY MD</name_or_title>
      <organization>VA NEBRASKA WESTERN IOWA VA HEALTHCARE</organization>
      <phone>4029954712</phone>
      <email>SRIRAM.RAMASWAMY@VA.GOV</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

